Plasma-derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors.
MC710
bypass
clinical trial
haemophilia
inhibitor
prophylaxis
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
15
11
2022
received:
25
08
2022
accepted:
17
11
2022
pubmed:
15
12
2022
medline:
21
3
2023
entrez:
14
12
2022
Statut:
ppublish
Résumé
Haemophilia B patients with factor IX inhibitors have particularly unmet needs for conventional therapy. Phase II/III clinical trial, multicentre, open-label, prospective, self-controlled study was conducted to assess MC710 prophylaxis in haemophilia B patients with inhibitors. We enrolled haemophilia patients who had received episodic or prophylactic treatment with bypassing agents up to that time. The participants continued their conventional therapy for 24 weeks and then MC710 was prophylactically infused intravenously every 2 or 3 days at 60 to 120 μg as FVIIa per kilogram of body weight for 24 weeks. The primary endpoint was the annual bleeding rate (ABR) requiring bypassing agents, which was compared intraindividually between the conventional therapy period and the MC710 prophylaxis period. A total of 11 male haemophilia B patients were enrolled. The median ABR ratio for each participant (the prophylaxis period ABR divided by the conventional therapy period ABR) was .33 (2.1/6.5), range from .00 to 3.77. ABR ratios for 9 of the 11 patients ranged from .00 to .60, and 3 of the 9 patients had zero bleeding events during the prophylaxis period. Meanwhile, ABR ratios for the remaining two patients were 2.53 and 3.77, respectively. Although a fibrinogen decrease recovered by the dose reduction was reported for only one participant as the sole adverse drug reaction in this study, no thrombotic events or other safety concerns were reported. MC710 prophylaxis is considered to be decrease the bleeding rate in haemophilia B patients with inhibitors without safety concerns.
Substances chimiques
MC710
0
Factor X
9001-29-0
Factor VIIa
EC 3.4.21.21
Factor VIII
9001-27-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
456-465Informations de copyright
© 2022 The Authors. Haemophilia published by John Wiley & Sons Ltd.
Références
Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
Acharya SS. Advances in hemophilia and the role of current and emerging prophylaxis. Am J Manag Care. 2016;22(5 Suppl):s116-25.
Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59-72.
Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia. 1996;2(1):28-31.
Warrier I. ITI in hemophilia B: possibilities and problems. International Monitor of Haemophilia; 2000;8(2):3-6.
World Federation of Hemophilia Annual Global Survey 2020. Accessed April 8, 2022. https://www1.wfh.org/publications/files/pdf-2045.pdf
Yoshioka A, Kamisue S, Tanaka I, et al. Anamnestic response following infusion of prothrombin complex concentrates (PCC) and activated prothrombin complex concentrates (APCC) in haemophilia A patients with inhibitors. Blood Coagul Fibrinolysis. 1991;2:51-58.
Nakatomi Y, Nakashima T, Gokudan S, et al. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent. Thrombosis Res. 2010;125(5):457-463.
Shirahata A, Fukutake K, Miyata J, et al. Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial. Haemophilia. 2012;18(1):94-101.
Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935-1939.
Shirahata A, Fukutake K, Takamatsu J, et al. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X(MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia. 2013;19(6):853-860.
Shinkoda Y, Shirahata A, Fukutake K, et al. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia. 2017;23(1):59-66.